Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer.
We are currently focusing our development efforts on picoplatin, a new generation platinum chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations. Picoplatin has an improved safety profile compared to existing platinum-based chemotherapeutics. It was designed to overcome platinum resistance associated with chemotherapy in solid tumors and delay time to relapse. We are studying picoplatin in multiple cancer indications, combinations and formulations.